Emcure and Gennova to resume mRNA collaboration with HDT
May 30, 2024
Source: drugdu
94
Emcure Pharmaceuticals and its biotech subsidiary, Gennova Biopharmaceuticals have amicably resolved all legal disputes with HDT Bio Corporation. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines, will once again collaborate on the development and commercialisation of mRNA vaccines.
The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields.
https://www.business-standard.com/companies/news/emcure-gennova-settle-legal-dispute-with-us-based-hdt-bio-sign-agreement-124052300762_1.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
- Regeneron’s midlife crisis November 22, 2024
- This “excellent hospital director” took the initiative to explain the problem November 22, 2024
- The director of the National Medical Insurance Bureau expressed his position to promote direct settlement of medical insurance November 22, 2024
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
